Safety and efficacy of glycopeptide antibiotics

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue SUPPL. 2, 2005, Pages

  Finch, R G ^a   Eliopoulos, G M ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Dalbavancin; Oritavancin; Resistance; Teicoplanin; Vancomycin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFAMANDOLE; CEFAZOLIN; CEFTAZIDIME; CLOXACILLIN; CORTICOSTEROID; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; FLUCLOXACILLIN; GENTAMICIN; LINEZOLID; METICILLIN; METRONIDAZOLE; MORPHINE; MOXIFLOXACIN; NEW DRUG; ORITAVANCIN; OXACILLIN; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VANCOMYCIN DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BETA HEMOLYTIC STREPTOCOCCUS; BULLOUS SKIN DISEASE; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CREATININE BLOOD LEVEL; DIZZINESS; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FLUSHING; GRAM POSITIVE BACTERIUM; HEARING LOSS; HEART ARREST; HEART DISEASE; HUMAN; HYPOTENSION; INTERSTITIAL NEPHRITIS; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUCOSAL BLEEDING; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; OUTPATIENT CARE; PHLEBITIS; POSTOPERATIVE INFECTION; PRURITUS; REVIEW; SKIN MANIFESTATION; STREPTOCOCCUS PNEUMONIAE; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TINNITUS; TOXIC EPIDERMAL NECROLYSIS; VANCOMYCIN RESISTANT ENTEROCOCCUS; VERTIGO;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; TEICOPLANIN; VANCOMYCIN;

EID: 15844371621     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki004     Document Type: Review

References (108)

1. Cooper, G. L. & Given, D. B. (1986). Vancomycin. A Comprehensive Review of 30 Years of Clinical Experience. Park Row Publishers, New York, NY, USA.
2. Kirst, H. A., Thompson, D. G. & Nicas, T. I. (1998). Historical yearly usage of vancomycin. Antimicrobial Agents and Chemotherapy 42, 1303-4.
3. Sztaricskai, F. & Pelyvás-Ferenczik, I. (1994). Chemistry of carbohydrate components. In Glycopeptide Antibiotics, 1st edn (Nagarajan, R., Ed.), p. 105. Marcel Dekker, New York, NY, USA.
4. Malabarba, A. & Ciabatti, R. (2001). Glycopeptide derivatives. Current Medicinal Chemistry 8, 1759-73.
5. Yao, R. C. & Crandall, L. W. (1994). Glycopeptides. Classification, occurrence and discovery. In Glycopeptide Antibiotics 1st edn (Nagarajan, R., Ed.), pp. 1-27. Marcel Dekker, New York, NY, USA.
6. Beauregard, D. A., Williams, D. H., Gwynn, M. N. et al. (1995). Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrobial Agents and Chemotherapy 39, 781-5.
7. Nicas, T. I., Zeckel, M. L. & Braun, D. K. (1997). Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance. Trends in Microbiology 5, 240-9.
8. Nicas, T. I., Mullen, D. L., Flokowitsch, J. E. et al. (1996). Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrobial Agents and Chemotherapy 40, 2194-9.
9. Allen, N. E. & Nicas, T. I. (2003). Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiological Reviews 26, 511-32.
10. Barrett, J. F. (2001). Oritavancin. Eli Lilly & Co. Current Opinion in Investigational Drugs 2, 1039-44.
11. Ge, M., Chen, Z., Onishi, H. R. et al. (1999). Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding to D-Ala-D-Ala. Science 284, 507-11.
12. Candiani, G., Abbondi, M., Borgonovi, M. et al. (1999). In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. Journal of Antimicrobial Chemotherapy 44, 179-92.
13. Judice, J. K. & Pace, J. L. (2003). Semi-synthetic glycopeptide antibiotics. Bioorganic & Medicinal Chemistry Letters 13, 4165-8.
14. Debabov, D. V., Higgins, D. L., Chang, R. et al. (2004). The role of membrane permeabilization in the mode of action of telavancin against vancomycin-sensitive and -resistant enterococci. In Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract C1-952, p. 71. American Society for Microbiology, Washington, DC, USA.
15. Higgins, D. L., Chang, R., Debabov, D. V. et al. (2004). Telavancin bactericidal activity against Staphylococcus aureus is mediated by multiple mechanisms. In Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract C1-953, p. 72. American Society for Microbiology, Washington, DC, USA.
16. Ballow, C. H., Jones, R. N., Biedenbach, D. J. et al. (2002). A multicenter evaluation of linezolid antimicrobial activity in North America. Diagnostic Microbiology and Infectious Disease 43 75-83.
17. Woodford, N. (1998). Glycopeptide-resistant enterococci: a decade of experience. Journal of Medical Microbiology 47, 849-62.
18. Henwood, C. J., Livermore, D. M., Johnson, A. P. et al. (2000). Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. Journal of Antimicrobial Chemotherapy 46, 931-40.
19. Zeckel, M. L., Preston, D. A. & Allen, B. S. (2000). In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study. Antimicrobial Agents and Chemotherapy 44, 1370-4.
20. Hershberger, E., Aeschlimann, J. R., Moldovan, T. et al. (1999). Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampicin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods. Antimicrobial Agents and Chemotherapy 43, 717-21.
21. Streit, J. M., Fritsche, T. R., Sader, H. S. et al. (2004). Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagnostic Microbiology and Infectious Disease 48, 137-43.
22. King, A., Phillips, I. & Kaniga, K. (2004). Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 53, 797-803.
23. Turnidge, J. & Grayson, M. L. (1993). Optimum treatment of staphylococcal infections. Drugs 45, 353-66.
24. Ziglam, H. M. & Finch, R. G. (2001). Limitations of presently available glycopeptides in the treatment of Gram-positive infection. Clinical Microbiology and Infection 7, Suppl. 4, 53-65.
25. Mutnick, A. H., Biedenbach, D. J., Turnidge, J. D. et al. (2002). Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY antimicrobial surveillance program, 1998-2000. Diagnostic Microbiology and Infectious Disease 43, 65-73.
26. Herold, B. C., Immergluck, L. C., Maranan, M. C. et al. (1998). Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. Journal of the American Medical Association 279, 593-8.
27. Fey, P. D., Said-Salim, B., Rupp, M. E. et al. (2003). Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 47, 196-203.
28. Dufour, P., Gillet, Y., Bes, M. et al. (2002). Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clinical Infectious Diseases 35, 819-24.
29. Karchmer, A. W. (2000). Nosocomial bloodstream infections: organisms, risk factors, and implications. Clinical Infectious Diseases 31, Suppl. 4, 139-43.
30. Salminen, U.-S., Viljanen, T. U. T., Valtonen, V. V. et al. (1999). Ceftriaxone versus vancomycin prophylaxis in cardiovascular surgery. Journal of Antimicrobial Chemotherapy 44 287-90.
31. Spelman, D., Harrington, G., Russo, P. et al. (2002). Clinical, microbiological, and economic benefit of a change in antibiotic prophylaxis for cardiac surgery. Infection Control and Hospital Epidemiology 23, 402-4.
32. Periti, P., Mini, E. & Mosconi, G. (1998). Antimicrobial prophylaxis in orthopaedic surgery: the role of teicoplanin. Journal of Antimicrobial Chemotherapy 41, 329-40.
33. Sanderson, P. J. (1998). Prophylaxis in orthopaedic implant surgery - should we use a glycopeptide? Journal of Antimicrobial Chemotherapy 41, 322-5.
34. Maki, D. G., Bohn, M. J., Stolz, S. M. et al. (1992). Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial. Journal of Thoracic and Cardiovascular Surgery 104, 1423-34.
35. Finkelstein, R., Rabino, G., Mashiah, T. et al. (2002). Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. Journal of Thoracic and Cardiovascular Surgery 123 326-32.
36. Wilson, W. R., Karchmer, A. W., Dajani, A. S. et al. (1995). Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. Journal of the American Medical Association 274, 1706-13.
37. Small, P. M. & Chambers, H. F. (1990). Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrobial Agents and Chemotherapy 34, 1227-31.
38. Levine, D. P., Fromm, B. S. & Reddy, B. R. (1991). Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Annals of Internal Medicine 115, 674-80.
39. Chambers, H. F., Miller, R. T. & Newman, M. D. (1988). Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Annals of Internal Medicine 109, 619-24.
40. Kucers, A. (1997). Teicoplanin. In The Use of Antibiotics. A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs, 5th edn (Kucers, A., Crowe, S. M., Grayson, M. L. et al., Eds), pp. 791-801. Butterworth-Heinemann, Oxford, UK.
41. D'Agata, E. M. (2002). Antimicrobial-resistant, Gram-positive bacteria among patients undergoing chronic hemodialysis. Clinical Infectious Diseases 35, 1212-8.
42. Fridkin, S. K., Hageman, J., McDougal, L. K. et al. (2003). Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clinical Infectious Diseases 36, 429-39.
43. Bartlett, J. G. (2002). Antibiotic-associated diarrhea. New England Journal of Medicine 346, 334-40.
44. Johnson, S. & Gerding, D. N. (1998). Clostridium difficile- associated diarrhea. Clinical Infectious Diseases 26, 1027-36.
45. Stevens, D. L., Herr, D., Lampiris, H. et al. (2002). Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clinical Infectious Diseases 34, 1481-90.
46. Rubinstein, E., Cammarata, S., Oliphant, T. et al. (2001). Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clinical Infectious Diseases 32 402-12.
47. Fagon, J.-Y., Patrick, H., Haas, D. W. et al. (2000). Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. American Journal of Respiratory and Critical Care Medicine 161, 753-62.
48. Calain, P., Krause, K. H., Vaudaux, P. et al. (1987). Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. Journal of Infectious Diseases 155, 187-91.
49. Gilbert, D. N., Wood, C. A. & Kimbrough, R. C. (1991). Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon. Antimicrobial Agents and Chemotherapy 35, 79-87.
50. Van Laethem, Y., Hermans, P., De Wit, S. et al. (1988). Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. Journal of Antimicrobial Chemotherapy 21, Suppl. A, 81-7.
51. Fortun, J., Perez-Molina, J. A., Anon, M. T. et al. (1995). Right-sided endocarditis caused by Staphylococcus aureus in drug abusers. Antimicrobial Agents and Chemotherapy 39, 525-8.
52. Smith, S. R., Cheesebrough, J., Spearing, R. et al. (1989). Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrobial Agents and Chemotherapy 33, 1193-7.
53. Van der Auwera, P., Aoun, M. & Meunier, F. (1991). Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrobial Agents and Chemotherapy 35, 451-7.
54. Rolston, K. V., Nguyen, H., Amos, G. et al. (1994). A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. Journal of Infectious Diseases 169, 350-5.
55. Menichetti, F., Martino, P., Bucaneve, G. et al. (1994). Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with haematologic malignancies. Antimicrobial Agents and Chemotherapy 38, 2041-6.
56. Leport, C., Perronne, C., Massip, P. et al. (1989). Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients. Antimicrobial Agents and Chemotherapy 33, 871-6.
57. Venditti, M., Tarasi, A., Capone, A. et al. (1997). Teicoplanin in the treatment of enterococcal endocarditis: clinical and microbiological study. Journal of Antimicrobial Chemotherapy 40 449-52.
58. Schmit, J. L. (1992). Efficacy of teicoplanin for enterococcal infections: 63 cases and review. Clinical Infectious Diseases 15, 302-6.
59. Presterl, E., Graninger, W. & Georgopoulos, A. (1993). The efficacy of teicoplanin in the treatment of endocarditis caused by Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 31 755-66.
60. Lewis, P. J., Martino, P., Mosconi, G. et al. (1995). Teicoplanin in endocarditis: a multicentre, open European study. Chemotherapy 41, 399-411.
61. Periti, P., Stringa, G. & Mini, E. (1999). Comparative multicenter trial of teicoplanin versus cefazolin for antimicrobial prophylaxis in prosthetic joint implant surgery. Italian Study Group for Antimicrobial Prophylaxis in Orthopedic Surgery. European Journal of Clinical Microbiology and Infectious Diseases 18, 113-9.
62. Suter, F., Avai, A., Fusco, U. et al. (1994). Teicoplanin versus cefamandole in the prevention of infection in total hip replacement. European Journal of Clinical Microbiology and Infectious Diseases 13, 793-6.
63. Marroni, M., Cao, P., Fiorio, M. et al. (1999). Prospective, randomized, double-blind trial comparing teicoplanin and cefazolin as antibiotic prophylaxis in prosthetic vascular surgery. European Journal of Clinical Microbiology and Infectious Diseases 18, 175-8.
64. Saginur, R., Croteau, D. & Bergeron, M. G. (2000). Comparative efficacy of teicoplanin and cefazolin for cardiac operation prophylaxis in 3027 patients. The ESPRIT Group. Journal of Thoracic and Cardiovascular Surgery 120, 1120-30.
65. Selzer, E., Dorr, M. B., Goldstein, B. P. et al. (2003). Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clinical Infectious Diseases 37, 1298-303.
66. Southorn, P. A., Plevak, D. J., Wright, A. J. et al. (1986). Adverse effects of vancomycin administered in the perioperative period. Mayo Clinic Proceedings 61, 721-4.
67. Ackerman, B. H. & Bradsher, R. W. (1985). Vancomycin and red necks. Annals of Internal Medicine 102, 723-4.
68. Sahai, J., Healy, D. P., Shelton, M. J. et al. (1990). Comparison of vancomycin- and teicoplanin-induced histamine release and 'red man syndrome'. Antimicrobial Agents and Chemotherapy 34, 765-9.
69. Shuto, H., Sueyasu, M., Otsuki, S. et al. (1999). Potentiation of vancomycin-induced histamine release by muscle relaxants and morphine in rats. Antimicrobial Agents and Chemotherapy 43 2881-4.
70. Wong, J. T., Ripple, R. E., MacLean, J. A. et al. (1994). Vancomycin hypersensitivity: synergism with narcotics and 'desensitization' by a rapid continuous intravenous protocol. Journal of Allergy and Clinical Immunology 94, 189-94.
71. Cohen, E., Dadashev, A., Drucker, M. et al. (2002). Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. Journal of Antimicrobial Chemotherapy 49, 155-60.
72. Hsu, S. I. (2001). Biopsy-proved acute tubulointerstitial nephritis and toxic epidermal necrolysis associated with vancomycin. Pharmacotherapy 21, 1233-9.
73. Nousari, H. C., Costarangos, C. & Anhalt, G. J. (1998). Vancomycin-associated linear IgA bullous dermatosis. Annals of Internal Medicine 129, 507-8.
74. Bernstein, E. F. & Schuster, M. (1998). Linear IgA bullous dermatosis associated with vancomycin. Annals of Internal Medicine 129, 508-9.
75. Nousari, H. C., Kimyai-Asadi, A., Caeiro, J. P. et al. (1999). Clinical, demographic, and immunohistologic features of vancomycin-induced linear IgA bullous disease of the skin: report of 2 cases and review of the literature. Medicine (Baltimore) 78, 1-8.
76. Wood, M. J. (1996). The comparative efficacy and safety of teicoplanin and vancomycin. Journal of Antimicrobial Chemotherapy 37, 209-22.
77. Wilson, A. P. R. (1998). Comparative safety of teicoplanin and vancomycin. International Journal of Antimicrobial Agents 10 143-52.
78. Elting, L. S., Rubenstein, E. B., Kurtin, D. et al. (1998). Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 83, 2597-607.
79. Farber, B. F. & Moellering, R. C., Jr (1983). Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrobial Agents and Chemotherapy 23, 138-41.
80. Goetz, M. B. & Sayers, J. (1993). Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. Journal of Antimicrobial Chemotherapy 32, 325-34.
81. Rybak, M. J., Albrecht, L. M., Boike, S. C. et al. (1990). Nephrotoxicity of vancomycin, alone and with an aminoglycoside. Journal of Antimicrobial Chemotherapy 32, 679-87.
82. Codding, C. E., Ramseyer, L., Allon, M. et al. (1989). Tubulointerstitial nephritis due to vancomycin. American Journal of Kidney Diseases 14, 512-5.
83. Bergman, M., Glew, R. H. & Ebert, T. H. (1988). Acute interstitial nephritis associated with vancomycin therapy. Archives of Internal Medicine 148, 2139-40.
84. Eliopoulos, G. M. (1997). Vancomycin. In Infectious Diseases and Antimicrobial Therapy of the Ears, Nose and Throat, 1st edn (Johnson, J. T. & Yu, V. L., Eds), pp. 85-91. W.B. Saunders, Philadelphia, PA, USA.
85. Gendeh, B. S., Gibb, A. G., Aziz, N. S. et al. (1998). Vancomycin administration in continuous ambulatory peritoneal dialysis: the risk of ototoxicity. Otolaryngology Head and Neck Surgery 118, 551-8.
86. Sorrell, T. C. & Collignon, P. J. (1985). A prospective study of adverse reactions associated with vancomycin therapy. Journal of Antimicrobial Chemotherapy 16, 235-41.
87. Moise, P. A., Forrest, A., Birmingham, M. C. et al. (2002). The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. Journal of Antimicrobial Chemotherapy 50, 1017-26.
88. Smith, P. F. & Taylor, C. T. (1999). Vancomycin-induced neutropenia associated with fever: similarities between two immune-mediated drug reactions. Pharmacotherapy 19, 240-4.
89. Schwartz, M. D. (2002). Vancomycin-induced neutropenia in a patient positive for an antineutrophil antibody. Pharmacotherapy 22, 783-8.
90. Sanche, S. E., Dust, W. N. & Shevchuk, Y. M. (2000). Vancomycin-induced neutropenia resolves after substitution with teicoplanin. Clinical Infectious Diseases 31, 824-5.
91. Zenon, G. J., Cadle, R. M. & Hamill, R. J. (1991). Vancomycin-induced thrombocytopenia. Archives of Internal Medicine 151, 995-6.
92. Howard, C. E., Adams, L. A., Admire, J. L. et al. (1997). Vancomycin-induced thrombocytopenia: a challenge and rechallenge. Annals of Pharmacotherapy 31, 315-8.
93. Stevens, D. L., Harrison, M. S., Graham, D. R. et al. (2002). Linezolid iv/po versus vancomycin iv for the treatment of suspected or proven methicillin-resistant Staphylococcus spp. infection: a second randomized, open-label, clinical trial. In Program and Abstracts of the Fortieth Annual Meeting of the Infectious Diseases Society of America, Chicago, IL, 2002. Abstract 181, p. 76. Infectious Diseases Society of America, Alexandria, VA, USA.
94. Christie, D. J., van Buren, N., Lennon, S. S. et al. (1990). Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with leukemia. Blood 75, 518-23.
95. Barriere, S., Genter, F., Spencer, E. et al. (2004). Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. Journal of Clinical Pharmacology 44, 689-95.
96. Leighton, A., White, R., Chaudhari, U. et al. (2001). Stringent audiology assessments in a healthy volunteer study with the glycopeptide dalbavancin. In Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001 Abstract 2192, p. 37. American Society for Microbiology, Washington, DC, USA.
97. Wilson, A. P. R., Grüneberg, R. N. & Neu, H. C. (1993). Dosage recommendations for teicoplanin. Journal of Antimicrobial Chemotherapy 32, 792-6.
98. Terol, M. J., Sierra, J., Gatell, J. M. et al. (1993). Thrombocytopenia due to use of teicoplanin. Clinical Infectious Diseases 17, 927.
99. Anon. (1995). Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). American Journal of Infection Control 23, 87-94.
100. Carmeli, Y., Samore, M. H. & Huskins, C. (1999). The association between antecedent vancomycin treatment and hospital-acquired vancomycin- resistant enterococci: a meta-analysis. Archives of Internal Medicine 159, 2461-8.
101. Carmeli, Y., Eliopoulos, G. M. & Samore, M. H. (2002). Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerging Infectious Diseases 8, 802-7.
102. Fridkin, S. K., Lawton, R., Edwards, J. R. et al. (2002). Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerging Infectious Diseases 8, 702-7.
103. Centers for Disease Control and Prevention. (1997). Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. Morbidity and Mortality Weekly Report 46, 626-35.
104. Noble, W. C., Virani, Z. & Cree, R. G. (1992). Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiology Letters 72, 195-8.
105. Centers for Disease Control and Prevention. (2002). Staphylococcus aureus resistant to vancomycin - United States, 2002. Morbidity and Mortality Weekly Report 51, 565-7.
106. Centers for Disease Control and Prevention. (2002). Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. Morbidity and Mortality Weekly Report 51, 902.
107. Centers for Disease Control and Prevention. (2004). Vancomycin-resistant Staphylococcus aureus - New York, 2004. Morbidity and Mortality Weekly Report 53, 322-3.
108. Wilcox, M. H. & Fawley, W. (2001). Extremely low prevalence of UK Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Journal of Antimicrobial Chemotherapy 48, 144-5.